查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
北美鴉片類藥物市場規模、佔有率、趨勢分析報告：按按產品、用途、地區和細分市場預測，2023-2030 年
市場調查報告書
商品編碼
1362903

北美鴉片類藥物市場規模、佔有率、趨勢分析報告：按按產品、用途、地區和細分市場預測，2023-2030 年

North America Opioids Market Size, Share & Trends Analysis Report By Product (IR/Short-acting, ER/Long-acting), By Application (Pain Relief, Anesthesia,Cough Suppression), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

北美鴉片類藥物市場成長與趨勢

Grand View Research, Inc. 的一項新研究顯示，從 2023 年到 2030 年，北美鴉片類藥物市場預計將以 0.8% 的複合年複合成長率成長，到 2030 年達到 153 億美元。

有利的法規和醫療改革將為開發新的防濫用鴉片類藥物的研發和商業化工作提供有利的環境，從而在預測期內促進產業成長。此外，大公司正在投入大量資金開發防濫用技術，旨在使藥物不易被竄改。其他活動包括使用物理或化學屏障來阻止鴉片類藥物的方便提取，在製劑中添加驅避劑以在提取時產生不良影響，以及依靠酶活性將其轉化為活性形式。例子包括鴉片類藥物的製劑前藥。

這種防篡改鴉片類製劑有望減少誤用的發生率。

鴉片類藥物是慢性疼痛管理的支柱，用於緩解各種疼痛狀況。鴉片類藥物，包括可待因和嗎啡，常用作止咳藥。可待因被認為是止咳藥的黃金標準，因為它幾乎沒有副作用。此外，由於這些麻醉劑作用於胃腸道受體，因此它們也用於治療大腸激躁症引起的腹瀉。此外，週邊作用的洛哌丁胺常用於控制腹瀉。因此，鴉片類藥物市場的有益成長在於其在治療咳嗽、腹瀉和疼痛等多種病症方面的用途。

北美鴉片類藥物市場報告亮點

  • 到 2022 年，緩釋性鴉片類藥物市場將佔最大佔有率，超過 53.8%。該領域的主導地位是由於這些藥物在慢性疼痛治療​​中的高利用率以及創新劑型（例如經皮吸收貼片）的開發。
  • 由於頻繁的產品召回以及與其使用相關的嚴重副作用，含有嗎啡和可待因的速釋劑型的市場佔有率預計將下降。
  • 按用途來看，止痛領域佔2022年銷售額的最大佔有率。化療和放射線治療期間引起的大量疼痛是癌症領域擴大採用這些藥物的一個主要要素。
  • 術後疼痛管理領域預計將成為疼痛緩解類別中成長最快的用途。由於其在術後疼痛管理中的高度適用性，預計外科手術數量的增加將在不久的將來推動鴉片類藥物滲透到領域。
  • 2022年，美國以95.6%的銷售佔有率佔據市場主導地位。主要要素之一是老年人口的增加，在臨床上更罹患類風濕性關節炎等末期疾病，正在對該市場產生積極影響。
  • 此外，擴大使用鴉片類藥物來治療創傷和損傷、嚴重慢性殘疾疾病和手術後的疼痛，也推動了北美地區的市場成長。
  • 由於癌症疼痛、肌肉骨骼疾病和術後疼痛等各種疼痛相關疾病的患病不斷增加而產生的需求，預計加拿大在預測期內將以 1.2% 的最快速度成長。此外，加拿大高齡化，進一步增加了對鴉片類藥物的需求。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 北美鴉片類藥物市場變數、趨勢與範圍

  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 普及和成長預測圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 北美鴉片類藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 北美鴉片類藥物：產品估算與趨勢分析

  • 北美鴉片類藥物市場：要點
  • 北美鴉片類藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 速效/短效鴉片類藥物
    • 2018年至2030年速效/短效鴉片類藥物市場估計與預測
    • 可待因
    • 羥考酮
    • 氫可酮
    • 芬太尼
    • 嗎啡
    • 羥基嗎啡酮
    • 羥嗎啡酮
    • 丙氧芬
    • 其他
  • 緩釋性/長效型鴉片類藥物
    • 2018 年至 2030 年緩釋性/長效鴉片類藥物市場估計與預測
    • 羥考酮
    • 氫可酮
    • 美沙酮
    • 芬太尼
    • 嗎啡
    • 羥嗎啡酮
    • 他噴他多
    • 丁丙諾啡
    • 氫嗎啡酮
    • 其他

第5章 北美鴉片類藥物市場：用途估算與趨勢分析

  • 北美鴉片類藥物市場：要點
  • 北美鴉片類藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 止痛藥
  • 麻醉
  • 止咳藥
  • 止瀉
  • 戒成癮

第6章 北美鴉片類藥物市場：區域估計與趨勢分析

  • 區域展望
  • 北美鴉片類藥物市場（按地區）：主要市場要點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Purdue Pharma LP
    • Janssen Global Services, LLC
    • Hikma Pharmaceuticals PLC
    • Pfizer Inc.
    • AbbVie Inc.
    • Sanofi
    • Sun Pharmaceutical Industries Ltd.
    • Mallinckrodt Pharmaceuticals
    • Endo Pharmaceuticals
    • Teva Pharmaceutical Industries
Product Code: GVR-1-68038-075-0

North America Opioids Market Growth & Trends:

The North America opioids market is expected to reach USD 15.3 billion by 2030, growing at an estimated CAGR of 0.8% from 2023 to 2030, according to a new study by Grand View Research, Inc.. Favorable regulations and healthcare reforms are providing an environment, conducive for research and development as well as commercialization efforts directed toward the development of novel abuse-deterrent opioids, to flourish and drive the industry growth during the forecast period. Furthermore, the key players are deploying large funds in the development of abuse-deterrent technology wherein drugs are designed to be tamper resistant. This is achieved through alterations involving, among others, the use of physical or chemical barriers to resist convenient extraction of the opioids, the addition of an aversive agent to the formulation that would yield an unpleasant effect upon its extraction, and the formulation of opioid prodrugs that are dependent on enzymatic activity in order to be rendered to their active forms. These tamper-resistant opioid drug forms are anticipated to mitigate the incidence of their misuse.

Opioids are the mainstay of chronic pain management that is used to alleviate varied pain conditions. Opiates including codeine and morphine are frequently employed as cough suppression medication. Codeine is considered as a gold standard for cough suppression since it has minimal side effects. Moreover, these narcoticsare used in the treatment of irritable bowel syndrome-induced diarrhea since they act on gastrointestinal receptors. In addition, peripherally acting loperamide is commonly used to suppress diarrhea. Thus, theprofitable growth of the Opioid Market lies in its breadth of applications in the management of diverse conditions including cough, diarrhea, and pain.

North America Opioids Market Report Highlights:

  • The extended-release opioids segment accounted for the largest share over 53.8% in 2022. The dominance of the segment is attributed to the high usage of these drugs for chronic pain management and the development of innovative dosage forms, such as transdermal patches.
  • Market share of the immediate-release dosage forms including morphine and codeine, is expected to decline owing to the frequent product recalls and severe side effects associated with their use.
  • In terms of applications, The pain relief segment dominated the market with the largest revenue share in 2022. The extensive amount of pain caused during chemotherapy and radiotherapy are the primary factors resulting in the increasing incorporation of these drugs in the cancer segment.
  • The post-operative pain management segment is expected to be the fastest growing application in the pain relief category. As a result of their high applicability in post- surgical pain management, the rise in number of surgical procedures is expected to fuel the sector penetration of opioids in the near future.
  • The U.S. dominated the market with the highest revenue share of 95.6% in 2022. One of the major determinants is the growing geriatric population with clinically demonstrated susceptibility to terminal conditions, such as rheumatoid arthritis, is positively impacting this vertical.
  • In addition, the increasing adoption of opioids for pain management related to trauma and injury cases, in severe and chronic disabling diseases, and in cases of post-surgical pain, is driving the growth of the market in the North America region
  • The Canada is expected to grow at the fastest growth rate of 1.2% over the forecast period owing to the demand arising from the increasing prevalence of various pain-related conditions, such as cancer-related pain, musculoskeletal disorders, and post-operative pain. In addition, the growing aging population in Canada has further contributed to the demand for opioids.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. North America Opioids Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. North America Opioids Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. North America Opioids: Product Estimates & Trend Analysis

  • 4.1. North America Opioids Market: Key Takeaways
  • 4.2. North America Opioids Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Immediate Release/ Short-acting Opioids
    • 4.3.1. Immediate release/ Short acting opioids market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2. Codeine
      • 4.3.2.1. Codeine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3. Oxycodone
      • 4.3.3.1. Oxycodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.4. Hydrocodone
      • 4.3.4.1. Hydrocodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.5. Fentanyl
      • 4.3.5.1. Fentanyl market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.6. Morphine
      • 4.3.6.1. Morphine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.7. Hydroxymorphone
      • 4.3.7.1. Hydroxymorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.8. Oxymorphone
      • 4.3.8.1. Oxymorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.9. Propoxyphene
      • 4.3.9.1. Propoxyphene market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.10. Others
      • 4.3.10.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Extended Release/Long-acting Opioids
    • 4.4.1. Extended release/Long-acting opioids market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Oxycodone
      • 4.4.2.1. Oxycodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Hydrocodone
      • 4.4.3.1. Hydrocodone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Methadone
      • 4.4.4.1. Methadone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Fentanyl
      • 4.4.5.1. Fentanyl market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Morphine
      • 4.4.6.1. Morphine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.7. Oxymorphone
      • 4.4.7.1. Oxymorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.8. Tapentadol
      • 4.4.8.1. Tapentadol market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.9. Buprenorphine
      • 4.4.9.1. Buprenorphine market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.10. Hydromorphone
      • 4.4.10.1. Hydromorphone market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.11. Others
      • 4.4.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. North America Opioids Market: Application Estimates & Trend Analysis

  • 5.1. North America Opioids Market: Key Takeaways
  • 5.2. North America Opioids Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Pain Relief
    • 5.3.1. Pain relief market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.2. Cancer Pain
      • 5.3.2.1. Cancer pain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.3. Post-Operative Care
      • 5.3.3.1. Post-operative care market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.4. Lower Back Pain
      • 5.3.4.1. Lower back pain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.5. Orthopedic
      • 5.3.5.1. Orthopedic market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.6. Neuropathic
      • 5.3.6.1. Neuropathic market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.3.7. Fibromyalgia
      • 5.3.7.1. Fibromyalgia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Anesthesia
    • 5.4.1. Anesthesia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Cough Suppression
    • 5.5.1. Cough suppression market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Diarrhea Suppression
    • 5.6.1. Diarrhea suppression market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. De-addiction
    • 5.7.1. De-addiction market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. North America Opioids Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. North America Opioids Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Purdue Pharma L.P.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Janssen Global Services, LLC
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Hikma Pharmaceuticals PLC
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Pfizer Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. AbbVie Inc.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Sanofi
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Sun Pharmaceutical Industries Ltd.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Mallinckrodt Pharmaceuticals
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Endo Pharmaceuticals
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Teva Pharmaceutical Industries
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America opioids market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America opioids market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America opioids market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. opioids market, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. opioids market, by application, 2018 - 2030 (USD Million)
  • Table 7 Canada opioids market, by product, 2018 - 2030 (USD Million)
  • Table 8 Canada opioids market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Opioids: Market outlook
  • Fig. 9 Opioids: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 North America opioids market driver impact
  • Fig. 14 North America opioids market restraint impact
  • Fig. 15 North America opioids market strategic initiatives analysis
  • Fig. 16 North America opioids market: Product movement analysis
  • Fig. 17 North America opioids market: Product outlook and key takeaways
  • Fig. 18 Immediate release/ Short acting opioids market estimates and forecasts, 2018 - 2030
  • Fig. 19 Codeine market estimates and forecasts, 2018 - 2030
  • Fig. 20 Oxycodone market estimates and forecasts, 2018 - 2030
  • Fig. 21 Hydrocodone market estimates and forecasts, 2018 - 2030
  • Fig. 22 Fentanyl market estimates and forecasts, 2018 - 2030
  • Fig. 23 Morphine market estimates and forecasts, 2018 - 2030
  • Fig. 24 Hydroxymorphone market estimates and forecasts, 2018 - 2030
  • Fig. 25 Oxymorphone market estimates and forecasts, 2018 - 2030
  • Fig. 26 Propoxyphene market estimates and forecasts, 2018 - 2030
  • Fig. 27 Others market estimates and forecasts, 2018 - 2030
  • Fig. 28 North America opioids market: Application movement analysis
  • Fig. 29 North America opioids market: Application outlook and key takeaways
  • Fig. 30 Extended release/Long acting opioids market estimates and forecasts, 2018 - 2030
  • Fig. 31 Oxycodone market estimates and forecasts, 2018 - 2030
  • Fig. 32 Hydrocodone market estimates and forecasts, 2018 - 2030
  • Fig. 33 Methadone market estimates and forecasts, 2018 - 2030
  • Fig. 34 Fentanyl market estimates and forecasts, 2018 - 2030
  • Fig. 35 Morphine market estimates and forecasts, 2018 - 2030
  • Fig. 36 Oxymorphone market estimates and forecasts, 2018 - 2030
  • Fig. 37 Tapentadol market estimates and forecasts, 2018 - 2030
  • Fig. 38 Buprenorphine market estimates and forecasts, 2018 - 2030
  • Fig. 39 Hydromorphone market estimates and forecasts, 2018 - 2030
  • Fig. 40 Others market estimates and forecasts, 2018 - 2030
  • Fig. 41 North America opioids market: Regional movement analysis
  • Fig. 42 North America opioids market: Regional outlook and key takeaways
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030
  • Fig. 44 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030